NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings (Nasdaq: NTHI) announced that CEO Amir F. Heshmatpour purchased 30,000 shares on the open market on November 13, 2026.
His 2026 open-market purchases total 371,000 shares for more than $1.5 million, including 180,000 shares in November. He used personal funds; NeOnc issued no shares. Since the August 12, 2026, topline Phase 2a results for intranasal NEO100, he has purchased 291,000 shares for more than $1 million. NeOnc has an FDA Type B End-of-Phase meeting scheduled for early January 2027 to seek feedback on a potential accelerated approval pathway and a proposed Phase 3 confirmatory trial.
NeOnc Technologies Holdings (NASDAQ: NTHI) is presenting updated findings from two investigational brain cancer programs at the Society for Neuro-Oncology meeting.
NEO100's Phase 2a study reported 48.9% six-month progression-free survival versus a 20% historical benchmark (p=0.0047), with median overall survival of 26.1 months in 24 patients. No treatment-related Grade 3 or higher adverse events were reported. NEO212 completed Phase 1 dose escalation with no observed myelosuppression, or suppression of blood-cell production, and two objective responses; both patients remained on treatment for more than 20 months.
An FDA meeting in early January 2027 will address NEO100's potential accelerated approval pathway and proposed Phase 3 trial. A November 23 meeting will address NEO212's next-stage development. Recent insider purchases and an Abu Dhabi research memorandum accompany the clinical updates.
NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour purchased another 70,000 shares as the company prepares for FDA discussions on NEO100. The purchases totaled approximately $294,500, bringing his November 5–11 purchases to 150,000 shares costing approximately $563,582. His reported direct holdings reached 3,333,000 shares.
The FDA granted a Type B End-of-Phase meeting for early January 2027. NeOnc plans to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma and seek agreement on its proposed Phase 3 trial. Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation November 13; a NEO212 FDA meeting follows November 17. Short interest reached approximately 921,000 shares on October 30, versus 876,682 on October 15.
NeOnc Technologies Holdings (NASDAQ: NTHI) reported additional insider buying as it prepares for FDA discussions on its investigational brain cancer therapy NEO100.
CEO Amir Heshmatpour purchased 80,000 shares, bringing his direct holdings to 3,333,000 shares; Chief Medical Officer Thomas Chen bought 5,016 shares. An FDA meeting scheduled for early January 2027 will address a potential accelerated approval pathway and proposed Phase 3 study. Two November 13 presentations will cover updated NEO100 results and NEO212 Phase 1 findings.
Previously announced NEO100 Phase 2a results showed six-month progression-free survival—patients alive without disease worsening—of 48.9% versus a 20% historical benchmark. Median overall survival was 26.09 months, with no major toxicities reported. An October memorandum with the Department of Health – Abu Dhabi outlines potential research collaboration.
NeOnc Technologies Holdings (NASDAQ: NTHI) secured an FDA meeting for early January 2027 to discuss potential accelerated approval of experimental NEO100.
The company seeks feedback on a 505(b)(2) New Drug Application for recurrent or progressive IDH-mutant grade 4 astrocytoma. Phase 2a six-month progression-free survival was 48.9% versus a protocol-defined 20% historical benchmark; the analysis included 24 patients with IDH1-mutant tumors, including 21 with grade 4 disease. No treatment-related Grade 3 or higher adverse events, serious adverse events or treatment discontinuations were reported.
NeOnc proposes a randomized Phase 3 comparison with investigator-selected standard chemotherapy, using overall survival as the primary endpoint. Updated NEO100 and NEO212 data are expected November 13, 2026; a separate NEO212 FDA meeting is scheduled November 17, 2026. NEO100's accelerated approval pathway remains under discussion.
NeOnc Technologies Holdings (NTHI) has secured an FDA meeting to discuss a potential accelerated approval pathway for intranasal NEO100. Scheduled for early January 2027, the meeting concerns recurrent or progressive IDH-mutant grade 4 astrocytoma. NeOnc plans to seek feedback on whether its data support an accelerated-approval application and agreement on a randomized Phase 3 trial using overall survival as its primary endpoint.
At the June 24, 2026 interim data cutoff, Phase 2a six-month progression-free survival was 48.9%, exceeding the protocol-defined 20% standard-of-care benchmark. Median overall survival was 26.1 months. No treatment-related Grade 3 or higher adverse events were reported. The meeting grant is not an approval of NEO100.
NeOnc Technologies Holdings (NTHI) announced that CEO Amir F. Heshmatpour purchased 80,000 shares on the open market on November 5, 6 and 9, 2026. The purchases totaled $269,082, at a weighted average of approximately $3.36 per share. He used personal funds; NeOnc issued no shares. His 2026 open-market purchases total 271,000 shares for approximately $1.11 million.
In the single-arm Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, six-month progression-free survival was 48.9% against a prespecified 20% benchmark (p = 0.0047). Median overall survival was 26.1 months. NEO212 completed Phase 1 dose escalation and established a recommended Phase 2 dose. Both programs have data presentations scheduled for November 13. An October memorandum of understanding with the Department of Health – Abu Dhabi covers advancing brain cancer research and exploring clinical trial opportunities, including pediatric oncology.
NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour purchased another 70,000 common shares on November 5 and 6 for approximately $230,510. He bought 30,000 shares at a weighted average price of approximately $3.17 and 40,000 at approximately $3.39, respectively. His reported beneficial ownership rose to approximately 7.77 million shares, including affiliated-entity holdings.
The purchases follow a November 5 update disclosing that Heshmatpour and Thomas C. Chen had bought a combined 160,016 shares for approximately $629,000 following NEO100 Phase 2a results. Reported in August, that study met its primary endpoint: six-month progression-free survival, or survival without disease worsening, was 48.9% against a prespecified 20% benchmark (p=0.0047). Updated NEO100 data and Phase 1 findings for NEO212, an investigational central nervous system cancer therapy, are scheduled for presentation November 13 at the Society for Neuro-Oncology annual meeting.
NeOnc Technologies Holdings (NTHI) reported a third-quarter 2026 net loss of $4.4 million and highlighted progress in its brain-cancer programs. Net loss narrowed from $8.6 million a year earlier; loss attributable to common stockholders was $7.3 million, or $0.28 per share. Operating expenses fell to $5.8 million from $6.9 million.
NEO100 met its Phase 2a primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% standard-of-care benchmark. Updated NEO100 and NEO212 data will be presented November 13, 2026. September financing raised approximately $15 million gross; approximately $5.8 million funded redemption of all Series A preferred shares, eliminating their potential dilution. Cash reached approximately $6.2 million at September 30, versus approximately $2.0 million at June 30. An October Abu Dhabi collaboration framework requires separate agreements and approvals for proposed activities.
NeOnc Technologies Holdings (NTHI) will present data from its two investigational brain cancer programs at the Society for Neuro-Oncology meeting on November 13, 2026.
The NEO100 presentation covers updated Phase 1/2a study results and compassionate-use experience in recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The NEO212 presentation addresses Phase 1 safety, pharmacokinetics—how a drug moves through the body—and early activity in temozolomide-resistant recurrent glioblastoma and brain metastases. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development.
NeOnc also outlined plans for a proposed pivotal trial targeting approximately 500 patients across 30 hospitals in three countries. That scale remains a development ambition, not completed enrollment. The presentation titles do not establish treatment efficacy.